HomeAI · summaries
Storia in 2 fonti
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
- ·
benzinga.com
Why Is Turn Therapeutics Stock Trading Higher Today? - Turn Therapeutics (NASDAQ:TTRX)
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.